RecruitingNCT06116110
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
A Prospective, Observational, Long-term Follow-up Study for Subjects Who Previously Received Zamtocabtagene Autoleucel in a United States Miltenyi Biomedicine-Sponsored Clinical Study
Sponsor
Miltenyi Biomedicine GmbH
Enrollment
150 participants
Start Date
May 15, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Received zamtocabtagene autoleucel in a Miltenyi Biomedicine-sponsored clinical study and have either completed the study or have discontinued early from the study.
- Provided written informed consent to participate in this study.
Exclusion Criteria1
- None
Interventions
OTHERLong-term Follow-Up
No intervention
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06116110
Related Trials
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
NCT0516951526 locations
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
NCT05006716120 locations
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
NCT06418204467 locations
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
NCT060263191 location
GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL
NCT068750631 location